Introduction:
Sanofi is investing US$3.75 million (€3.5 million) to open new bioproduction capacity at its facilities in Vitry-sur-Seine (Val dae Marne), Loe Trait (Seine-Maritime), and Lyon Gerland (Rhône) in France.
Features:
This new investment will result in the creation of over 500 jobs and significantly enhance capability to oversee the production of essential medicines from inception to completion, both now and in the future.
In Vitry-sur-Seine, €1 billion will be invested to build a new facility aimed at doubling the site's capacity for producing monoclonal antibodies.
Several biologics in development among 12 potential blockbusters, targeting conditions such as chronic obstructive pulmonary disorder (COPD), asthma, multiple sclerosis, and type 1 diabetes, could be produced in Vitry to meet the needs of millions of patients in France and globally. This investment is expected to create 350 jobs.
In Normandy, at the Loe Trait site, a €100 million investment is planned to expand capabilities for biologics formulation, filling, device assembly, and packaging.
This initiative will bolster the introduction of upcoming biologics and vaccines, alongside supporting the expanding demand for Dupixent®, currently approved for multiple inflammatory conditions and potentially for COPD, marking a significant advancement. The investment aims to generate 150 new job opportunities.
In Lyon Gerland, an investment of €10 million will be made to locate the production of TZield® in France.
Specifications:
Name Sanofi
Type New Construction
Budget US$3.75 million (€3.5)
